Thus, high levels of TGF-β1 secretion by HBMSCs may be an essential mechanism involved in the therapeutic effects of MSCs in promoting the spread of Tregs in IPF patients [94, 95]. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.